Dihydroergotoxine Mesilate
Brand names,
Dihydroergotoxine Mesilate
Analogs
Dihydroergotoxine Mesilate
Brand Names Mixture
Dihydroergotoxine Mesilate
Chemical_Formula
C33H45N5O5
Dihydroergotoxine Mesilate
RX_link
No information avaliable
Dihydroergotoxine Mesilate
fda sheet
Dihydroergotoxine Mesilate
msds (material safety sheet)
Dihydroergotoxine Mesilate
Synthesis Reference
No information avaliable
Dihydroergotoxine Mesilate
Molecular Weight
591.741 g/mol
Dihydroergotoxine Mesilate
Melting Point
No information avaliable
Dihydroergotoxine Mesilate
H2O Solubility
No information avaliable
Dihydroergotoxine Mesilate
State
Solid
Dihydroergotoxine Mesilate
LogP
2.615
Dihydroergotoxine Mesilate
Dosage Forms
Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet
Dihydroergotoxine Mesilate
Indication
For use as an adjunct therapy for patients with dementia
Dihydroergotoxine Mesilate
Pharmacology
Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Dihydroergotoxine Mesilate
Absorption
Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Dihydroergotoxine Mesilate
side effects and Toxicity
Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Dihydroergotoxine Mesilate
Patient Information
No information avaliable
Dihydroergotoxine Mesilate
Organisms Affected
Humans and other mammals